Table of Contents
At present, the demand in China’s blood products market is strong, but restricts by blood plasma supply and NDRC price limit, China’s blood products market has been developing steadily since 2005; in recent three years, this industry has maintained the growth rate of about 20%. Huidian Research estimated that the scale of China’s blood products market was CNY 17.28 billion in 2012.
The per capita blood products consumption of Chinese residents is extremely low, and there is a relatively large gap compares with the developed countries. China’s albumin supply has been tight, and the annual growth rate will be about 15% in the future. The per capita consumption of human immunoglobulin for intravenous injection is only 10% of the foreign countries, since 2004, the growth rate in this aspect has been maintaining at the level of more than 30%; at present, this application in small and medium-scale hospitals is still unpopular, and the development potential is relatively huge; as for the sales of coagulation factor products, China is still in its infancy, compares with foreign market share of 40%, China owns a broad market space.
Due to the shortage of blood plasma source, China’s blood products have been in short supply in recent years. Although the lot release volume of blood products in China has been increasing in recent years, the continuous economic growth, population aging trend and the changing of medication habits have determined the continuous increase of blood products demands, and the status of blood plasma shortage is difficult to change in the short term, which determines that China’s blood products will be in short supply for a quite long period of time. In this situation, the consumers almost have no bargaining power, and the industry’s profitability is strong; therefore, China’s blood products industry will continue to keep high prosperity in the future.
The concentration ratio of international blood products is very high, which is in oligopoly and determined by market demand; the relationship between supply and demand is balance, the market growth mainly depends on the introduction of new products and new adaptation diseases. However, China’s blood products are in the independent and closed state, and the industry is in the state of short supply. The industry is affected by policies and guided by government; the enterprises are relatively scattered but tend to concentrate. In a longer period in the future, the competitiveness of blood products enterprises will be determined by the ownership of blood plasma resources and comprehensive utilization of blood plasma.
“Research and Development Trend of China Blood Products Industry, 2013” firstly conducts a brief introduction of the global blood products development; and then, this report deeply analyzes the development of this industry in China, and the contents involve market scale, supply and demand, price, competitive landscape, industry policies and industry barriers; what’s more, this report also conducts specific analysis on China’s blood plasma resources, blood products market segments and key enterprises; finally, this report conducts a professional analysis on the development trend of China’s blood products industry, which can provide decision-making references for the investors.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Animal Blood Plasma Products and Derivatives Market (Derivatives Type - Immunoglobulin, Fibrinogen, Serum Albumin, and Fetal Bovine Serum; Application - Cell Culture Media, Food Industry, Pharmaceutical ...
The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...
Blood collection, processing, management devices & consumables are class of medical devices used for collecting the whole blood from the donor, segregating the collected blood into blood components like ...